Martin Shkreli won't cut individual Daraprim price after all

Martin Shkreli Won't Cut Individual Daraprim Price After All



Remember Martin Shkreli, arguably the most hated man in pharmaceuticals for raising the cost of a drug HIV patients regularly take by 5,000 percent? Well, he's getting some very unwanted attention again.

Shkreli is the Turing Pharmaceuticals CEO who inflated the cost of the parasite-fighting and lifesaving drug Daraprim from $13.50 to $750.

For more on Martin Shkreli​ scroll through the gallery below:
17 PHOTOS
Former drug company executive Martin Shkreli
See Gallery
Martin Shkreli won't cut individual Daraprim price after all
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S., June 26, 2017. REUTERS/Lucas Jackson
Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, center, and attorney Evan Greebel, left, exit federal court in New York, U.S., on Thursday, Dec. 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. Greebel is accused of conspiring with Shkreli in part of the scheme. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, exits federal court in New York, U.S., on Thursday, Dec. 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli, chief investment officer of MSMB Capital Management, sits for a photograph in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, works on a computer in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, sits behind a chess board in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli (L), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives for a hearing at U.S. Federal Court in Brooklyn, New York, U.S. October 14, 2016. REUTERS/Lucas Jackson
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs following a hearing at U.S. Federal Court in Brooklyn, New York, U.S., April 26, 2017. REUTERS/Brendan McDermid
Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives for a hearing at U.S. Federal Court in Brooklyn, New York, U.S. October 14, 2016. REUTERS/Lucas Jackson
Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at a U.S. Federal Court in New York, U.S., June 6, 2016. REUTERS/Lucas Jackson
Former drug executive Martin Shkreli exits the U.S. Federal Courthouse in the Brooklyn borough of New York February 3, 2016. REUTERS/Brendan McDermid
Martin Shkreli (top, R), former CEO of Turing Pharmaceuticals LLC, arrives before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington February 4, 2016. REUTERS/Joshua Roberts
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, right, exits federal court with his attorney Benjamin Brafman in the Brooklyn borough of New York, U.S., on Thursday, June 29, 2017. Shkreli is accused of engineering separate frauds tied to his control of two hedge funds he ran as well as�Retrophin Inc., a pharmaceutical company he founded in 2011. Photographer: Peter Foley/Bloomberg via Getty Images
Martin Shkreli (C), chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York December 17, 2015. REUTERS/Lucas Jackson
Bloomberg Best of the Year 2016: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals LLC, reacts during a House Committee on Oversight and Government Reform hearing on prescription drug prices in Washington, D.C., U.S., on Thursday, Feb. 4, 2016. Shkreli, who is no longer with Turing and faces federal fraud charges unrelated to the drugmaker, declined to make any comments to the committee. 'On the advice of counsel, I invoke my Fifth Amendment,' Shkreli said. Photographer: Pete Marovich/Bloomberg via Getty Images
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals LLC, smiles during a House Committee on Oversight and Government Reform hearing on prescription drug prices in Washington, D.C., U.S., on Thursday, Feb. 4, 2016. Shkreli, who is no longer with Turing and faces federal fraud charges unrelated to the drugmaker, declined to make any comments to the committee. 'On the advice of counsel, I invoke my Fifth Amendment,' Shkreli said. Photographer: Pete Marovich/Bloomberg via Getty Images
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE


Patients, the medical community and the media blasted Shkreli for the move, and eventually he did say he'd reverse the price increase.

But on Wednesday his company said in a press release that it would drop prices by 50 percent for hospitals, create smaller bottles with 30 pills and provide free starter packs in 2016. The company also said, "We pledge that no patient needing Daraprim will ever be denied access."

Sounds nice, right? Well, these changes might only affect bulk buys, since it seems as if the $750 price per pill is unchanged.

Shkreli previously said the company needed to increase the pill's price so it could do studies to improve the drug. But critics have questioned his company's ability to do sound scientific research.

Some presidential hopefuls have even used Shkreli and Turing as a part of their platforms for health care or a conversation about how they could regulate the pharmaceutical industry to avoid price hikes like these in the future.

This video includes an image from the U.S. National Library of Medicine.

More from AOL.com:
AP FACT CHECK: On climate science, most GOP candidates fail
Balloons, floats as NYC Thanksgiving parade gets underway
hris Hemsworth paid off his parents' debts

Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.